Clinical Trials

30 enrolled 7 charts

Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

880 enrolled

Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02884648 2026-02-06

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

35 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1 Recruiting

34 enrolled

Ovarian Neoplasms

NCT07340164 2026-01-14

TROY

116 enrolled

Ovarian Neoplasms, Recurrence

NCT07314619 2026-01-02

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

30 enrolled

Phase 1 Active not recruiting

Platinum-resistant Recurrent Ovarian Cancer (PROC)

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

352 enrolled

DermatologicGastrointestinalGynecologicSarcoma

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

38 enrolled

Ovarian Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

17 enrolled 14 charts

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

110 enrolled

Phase 4 Active not recruiting

Endometrial Neoplasms

NCT06121401 2025-09-17

IOLANTHE

190 enrolled

Carcinoma, Ovarian Epithelial

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT07146919 2025-08-28

ANGELICA

87 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Phase 1/2 Recruiting

35 enrolled

Cervical Adenocarcinoma

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

37 enrolled

Advanced Ovarian Cancer

NCT06540729 2025-07-08

DAB

39 enrolled

Ovarian Neoplasms

NCT06954584 2025-06-24

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Phase 3 Recruiting

424 enrolled

Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Ovarian Neoplasms

NCT05044871 2025-06-08

BRIGHT

108 enrolled

Phase 1/2 Not yet recruiting

Ovarian Neoplasms

NCT06990516 2025-05-25

SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

90 enrolled

Ovarian Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

38 enrolled 12 charts

Endometrial Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT01220154 2025-02-21

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Phase 1 Completed

9 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06827353 2025-02-14

OVNI-B

Recruiting

300 enrolled

Carcinoma, Ovarian Neoplasms

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

614 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03556839 2025-01-08

BEATcc

410 enrolled

Carcinoma, Uterine Cervical Neoplasms

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

20 enrolled

Ovarian Cancer Recurrent

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

105 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT03596281 2024-10-18

PEMBOV

Phase 1 Completed

47 enrolled

Ovarian Neoplasms

NCT04787289 2024-08-07

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

244 enrolled

DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Ovarian Neoplasms

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Phase 1 Completed

43 enrolled

Cervical Adenocarcinoma

NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

39 enrolled

Platinum-resistant Recurrent Ovarian Cancer

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

22 enrolled

Platinum-sensitive Relapsed Ovarian Cancer

NCT03093155 2024-05-14

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

78 enrolled 18 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

9 enrolled 9 charts

BreastGastrointestinalGynecologicThoracic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

50 enrolled

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03476798 2024-02-15

Clovis-001

49 enrolled 13 charts